Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) have earned an average rating of “Buy” from the thirteen brokerages that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold recommendation, ten have given a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $49.91.

A number of research analysts have recently issued reports on DYN shares. Chardan Capital reissued a “buy” rating and issued a $50.00 target price on shares of Dyne Therapeutics in a report on Friday, January 10th. HC Wainwright restated a “buy” rating and set a $55.00 price objective on shares of Dyne Therapeutics in a research report on Friday, January 10th. Raymond James upgraded shares of Dyne Therapeutics to a “strong-buy” rating in a research note on Thursday, December 12th. Guggenheim reissued a “buy” rating on shares of Dyne Therapeutics in a report on Friday, January 24th. Finally, JPMorgan Chase & Co. cut Dyne Therapeutics from an “overweight” rating to a “neutral” rating and dropped their target price for the stock from $43.00 to $35.00 in a research report on Thursday, October 24th.

Insider Activity

In related news, insider Oxana Beskrovnaya sold 2,334 shares of the business’s stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $28.12, for a total transaction of $65,632.08. Following the completion of the transaction, the insider now owns 201,685 shares in the company, valued at approximately $5,671,382.20. The trade was a 1.14 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Richard William Scalzo sold 1,455 shares of the company’s stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $28.12, for a total transaction of $40,914.60. Following the completion of the transaction, the senior vice president now owns 127,078 shares of the company’s stock, valued at $3,573,433.36. This trade represents a 1.13 % decrease in their position. The disclosure for this sale can be found here. 20.77% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Creative Planning grew its stake in Dyne Therapeutics by 41.5% in the 3rd quarter. Creative Planning now owns 10,605 shares of the company’s stock valued at $381,000 after buying an additional 3,111 shares during the last quarter. Values First Advisors Inc. acquired a new stake in Dyne Therapeutics in the 3rd quarter worth about $62,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Dyne Therapeutics by 24.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,631 shares of the company’s stock valued at $123,000 after purchasing an additional 709 shares during the period. China Universal Asset Management Co. Ltd. grew its position in shares of Dyne Therapeutics by 67.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 19,310 shares of the company’s stock worth $694,000 after purchasing an additional 7,812 shares in the last quarter. Finally, US Bancorp DE increased its holdings in shares of Dyne Therapeutics by 776.9% during the third quarter. US Bancorp DE now owns 1,368 shares of the company’s stock worth $49,000 after purchasing an additional 1,212 shares during the period. 96.68% of the stock is owned by institutional investors and hedge funds.

Dyne Therapeutics Stock Performance

DYN stock opened at $13.91 on Tuesday. The company’s 50 day moving average price is $19.16 and its 200 day moving average price is $29.34. The firm has a market capitalization of $1.42 billion, a price-to-earnings ratio of -3.91 and a beta of 1.11. Dyne Therapeutics has a fifty-two week low of $13.07 and a fifty-two week high of $47.45.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.